Home > Boards > US Listed > Biotechs >

Can-Fite BioPharma (CANF)

CANF RSS Feed
Add CANF Price Alert      Hide Sticky   Hide Intro
Moderator: midastouch017
Search This Board: 
Last Post: 5/28/2020 7:08:07 AM - Followers: 60 - Board type: Free - Posts Today: 0

Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and liver diseases.

The company platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company compounds bind with nM affinity to the A3AR and initiate de-regulation of the NF-kB and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects

 
 

The company pipeline drugs are synthetic, highly specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile. Piclidenoson (CF101), Can-Fite`s lead drug candidate, is an oral drug that has been successfully tested in animal models and is currently in Phase III clinical studies for the treatment of Rheumatoid Arthritis (RA) and Psoriasis. All human clinical studies have demonstrated this drug to have an excellent safety profile. In two Phase II studies where Piclidenoson has been given as a standalone drug, data indicated that it acted as a disease modifying anti-inflammatory drug in RA patients. The Phase II and the Phase II/III clinical studies in Psoriasis showed clinical activity and safety of the drug. Namodenoson (CF102), Can-Fite`s second drug candidate, is an oral drug currently being developed for the treatment of Liver Diseases including hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH). CF602 an allosteric modulator at the A3AR which has shown proof of concept in pre-clinical pharmacology studies and is earmarked for the treatment of sexual dysfunction. Can-Fite has a wealth of clinical experience which includes over 1200 patients who have participated in clinical trials conducted by the company.

Can-Fite has licensed Piclidenoson for the treatment of autoimmune diseases to Cipher Pharmaceuticals in Canada, to Gebro Pharma GmbH in Spain, Switzerland & Austria,  for RA to Kwang Dong in Korea and to CMS for RA and Psoriasis in China, Taiwan, Hong Kong, Macao.

Can-Fite has licensed Namodenoson for the treatment of Liver Cancer and NASH to Chong Kun Dang Pharmaceut in Korea and to CMS in China.

Can-Fite is collaborating with leading researchers from the US NIH and the Leiden University in the Netherlands.

 

Israeli Office

10 Bareket Street
Kiryat Matalon
P.O. Box 7537
Petah-Tikva 49170
ISRAEL (Directions)

Tel: +972-3-9241114
Fax: +972-3-9249378

General email:
info@canfite.co.il

 

Investor Relations
(800)716-4880
info@canfite.co.il 


 

USA Office

255 Bear Hill Road, Suite 2200
Waltham
MA 02451
USA

Tel: +972-3-9241114
Fax: +972-3-9249378

http://www.canfite.com/

 

CANF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CANF News: Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020 05/28/2020 07:00:00 AM
CANF News: Report of Foreign Issuer (6-k) 05/21/2020 07:13:58 AM
CANF News: Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent & Trademark Of... 05/21/2020 07:00:00 AM
CANF News: Report of Foreign Issuer (6-k) 05/18/2020 07:09:21 AM
CANF News: Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liv... 05/18/2020 07:00:00 AM
PostSubject
#1405  Sticky Note Can-Fite Reports Receives Notice Of Allowance For Namodenoson swanlinbar 05/21/20 07:18:53 AM
#1410   Can-Fite to Host First Quarter 2020 Financial Results midastouch017 05/28/20 07:08:07 AM
#1409   Best guess is traders used the patent PR InTheTrenches 05/26/20 09:12:37 PM
#1408   I have no idea for midastouch017 05/26/20 12:55:54 PM
#1407   added to the pile $$$$$$$$ kingsransome 05/26/20 12:26:06 PM
#1406   Loaded heavy on this earlier in the week keekee 05/22/20 09:23:08 AM
#1405   Can-Fite Reports Receives Notice Of Allowance For Namodenoson swanlinbar 05/21/20 07:18:53 AM
#1404   CANF added a few more today for the swanlinbar 05/18/20 12:56:35 PM
#1403   Can-Fite Reports Additional Findings from Successful Phase II midastouch017 05/18/20 07:34:00 AM
#1402   CANF news swanlinbar 05/18/20 07:14:28 AM
#1401   CANF in TASE today: midastouch017 05/17/20 11:02:07 AM
#1400   Roth Capital Reiterates Buy On Can-Fite w/ $20 pt... ~MulaGreen~ 05/16/20 10:24:42 AM
#1399   Bought some today 1.84,will be holding on for awhile swanlinbar 05/15/20 03:21:42 PM
#1398   Trying to analyze this PR, to see if InTheTrenches 05/15/20 11:59:15 AM
#1397   Thank you! midastouch017 05/15/20 11:41:41 AM
#1396   thanks for straightening me out your a good mensch shurtha2000 05/15/20 11:28:22 AM
#1395   Can Fite Received Approval for COVID-19 Clinical Trial midastouch017 05/15/20 11:19:25 AM
#1394   Really weird in my opinion how they handled shurtha2000 05/15/20 11:09:09 AM
#1393   Results?? on 40 patients @Rabin Medical center - shurtha2000 05/15/20 11:08:03 AM
#1392   Ph3 Picledenoson will soon be FDA approved for ~MulaGreen~ 05/15/20 08:28:59 AM
#1391   It would be even better upon midastouch017 05/15/20 07:55:59 AM
#1390   So it's here what we are patiently waiting for... ~MulaGreen~ 05/15/20 07:48:42 AM
#1389   Can-Fite Announces Pre-IND Submission to U.S. FDA for midastouch017 05/15/20 07:12:44 AM
#1388   WTF CANF LETS GO ALREADY!!! LemonsCapital 05/11/20 08:37:16 PM
#1387   Nice dd ..looks like i might get pAid LemonsCapital 04/19/20 04:02:24 AM
#1386   Read here Monday 4/20/2020 4PM Israel Time-9AM USA EST>>> ~MulaGreen~ 04/18/20 10:11:35 AM
#1385   The AH Volume yesterday of a mere 20K ~MulaGreen~ 04/17/20 03:18:30 PM
#1384   Thank you Spideyboy. Perhaps this was midastouch017 04/17/20 02:07:42 AM
#1383   Just listened to the webcast. Spideyboy 04/16/20 11:46:49 PM
#1382   Excellent results!!! webdev2016 04/16/20 11:11:19 PM
#1380   2.0200+0.2900 (+16.76%) midastouch017 04/16/20 04:27:30 PM
#1379   Looks like im getting paid tomorra... Great work $Canf LemonsCapital 04/16/20 04:16:03 PM
#1378   Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a midastouch017 04/16/20 10:46:07 AM
#1377   How are my Covid19 patients doing with Piclidenoson? ~MulaGreen~ 04/15/20 12:57:08 PM
#1376   adding a penny for tomorrow gtc @ $2.20 LemonsCapital 04/14/20 04:22:58 PM
#1375   Canf gtc @ 2.19 LemonsCapital 04/14/20 12:32:10 PM
#1374   each day im stuck im adding a penny LemonsCapital 04/14/20 12:31:35 PM
#1373   Fkn trash dis stock... Looks like im stuck LemonsCapital 04/14/20 11:42:45 AM
#1372   expect sell-off today edwardport 04/14/20 09:37:53 AM
#1371   CANF CCNews... ~MulaGreen~ 04/14/20 07:26:18 AM
#1370   Nope the poorman has no capital to invest... LemonsCapital 04/13/20 05:59:46 PM
#1368   * * $CANF Video Chart 04-13-2020 * * ClayTrader 04/13/20 04:05:57 PM
#1367   Then be a Poorman with your TickleTrading atm.eom ~MulaGreen~ 04/13/20 03:51:50 PM
#1366   no thanks lol LemonsCapital 04/13/20 03:11:32 PM
#1365   Edit your GTC to $8.21 eom. ~MulaGreen~ 04/13/20 02:25:11 PM
#1364   Long $canf @ $1.98 LemonsCapital 04/13/20 01:58:02 PM
#1363   $7! $7!! $7!!! Disobey at your own DUMB risk! keekee 04/13/20 12:09:48 PM
#1362   The fossil selling this...are toast. Click on my keekee 04/13/20 10:40:50 AM
#1361   I agree!!!eom ~MulaGreen~ 04/13/20 10:20:44 AM
#1360   CANF 2 x PH3 Deserves pps $7+... ~MulaGreen~ 04/13/20 10:20:10 AM
#1359   And my message to the DUMB gamblers selling keekee 04/13/20 09:58:22 AM
PostSubject